Abstract 170P
Background
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare primary hepatic malignancy considered to be a variant of hepatocellular carcinoma. It accounts for about ≈ 1-5% of all HCCs .Surgery (resection/liver transplantation) is the current standard treatment and remains the only potentially curative treatment option ; however, the role of chemotherapy is still controversial . Therefore, we conducted this study to evaluate the efficacy of chemotherapy in improving the survival of patients with Fibrolamellar hepatocellular carcinoma (FL-HCC).
Methods
Using SEER database, we extracted the data of 100 patients with FL-HCC from 2004 to 2014. There were 40 (40%) patients underwent surgery combined with chemotherapy, while 60(60%) of them received chemotherapy only. Patients’ demographics and staging system were assessed.
Results
Patients with FL-HCC had better outcomes when they received surgery alone compared to those who received surgery combined with chemotherapy, where overall 1-year relative survival rates were 98.3% and 95%, respectively (significant p value of 0.031).Subgroup analysis revealed that there is a highly significant P-value (< 0.0001) regarding both different age groups and staging system. On the other hand ;there is No significance for the p value was reported to the race or sex.Table:
170P
Variables | Survival of Patients | p value | |
---|---|---|---|
surgery combined with chemotherapy | Surgery alone | ||
Sex Male Female | 92.3% 100% | 100% 95.7% | 0.246 |
Age 0-19 20-39 40-59 60-79 | 100% 84.6% 100% 100%** | 100% 100% 100% 81.8% | <0.0001*** |
Race White Black Asian or Pacific Islander | 96.7% 100%** 85.7% | 98% 100% * | 0.838 |
staging I II IIIA IIIB IIIC IV | 100% 100%** 100% 100%** 100% 85.7% | 96.4% 100% 100% 100%** 100% 100% | <0.0001*** |
Highly significant P-value < 0.0001.
**few patients reported.
*NO recorded patients.
Conclusions
surgery alone without chemotherapy in patients with FL-HCC shows higher 1-year relative survival rates when compared to surgery combined with chemotherapy. So, we recommend surgery alone without chemotherapy as a superior modality for better survival. Further studies should be conducted on a larger number of patients to confirm the results. Keywords: Fibrolamellar hepatocellular carcinoma (FL-HCC), chemotherapy, surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yasmine Ashraf Mohamed Ali.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract